nodes	percent_of_prediction	percent_of_DWPC	metapath
Cycloserine—Neurological symptom—Altretamine—ovarian cancer	0.126	0.255	CcSEcCtD
Cycloserine—SLC36A2—gonad—ovarian cancer	0.0892	0.284	CbGeAlD
Cycloserine—SLC36A2—female reproductive system—ovarian cancer	0.0797	0.254	CbGeAlD
Cycloserine—SLC36A2—testis—ovarian cancer	0.0643	0.205	CbGeAlD
Cycloserine—DDC—Dopaminergic Neurogenesis—LMX1A—ovarian cancer	0.0435	0.228	CbGpPWpGaD
Cycloserine—Paresis—Chlorambucil—ovarian cancer	0.0372	0.075	CcSEcCtD
Cycloserine—Paresis—Topotecan—ovarian cancer	0.0331	0.0668	CcSEcCtD
Cycloserine—DDC—embryo—ovarian cancer	0.0329	0.105	CbGeAlD
Cycloserine—Paresis—Vinorelbine—ovarian cancer	0.0283	0.0571	CcSEcCtD
Cycloserine—Neurological symptom—Paclitaxel—ovarian cancer	0.023	0.0464	CcSEcCtD
Cycloserine—DDC—female reproductive system—ovarian cancer	0.0199	0.0635	CbGeAlD
Cycloserine—SLC36A2—Amino acid and oligopeptide SLC transporters—SLC5A5—ovarian cancer	0.0193	0.101	CbGpPWpGaD
Cycloserine—Drug hypersensitivity—Paclitaxel—ovarian cancer	0.0172	0.0348	CcSEcCtD
Cycloserine—DDC—testis—ovarian cancer	0.0161	0.0512	CbGeAlD
Cycloserine—DDC—Amine-derived hormones—SLC5A5—ovarian cancer	0.0151	0.0792	CbGpPWpGaD
Cycloserine—Vertigo—Altretamine—ovarian cancer	0.015	0.0303	CcSEcCtD
Cycloserine—DDC—Dopamine metabolism—SOD1—ovarian cancer	0.0147	0.0771	CbGpPWpGaD
Cycloserine—Convulsion—Altretamine—ovarian cancer	0.0144	0.0292	CcSEcCtD
Cycloserine—DDC—lymph node—ovarian cancer	0.0117	0.0371	CbGeAlD
Cycloserine—SLC36A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC5A5—ovarian cancer	0.0114	0.0596	CbGpPWpGaD
Cycloserine—DDC—Parkinsons Disease Pathway—PARK2—ovarian cancer	0.01	0.0525	CbGpPWpGaD
Cycloserine—Drug hypersensitivity—Epirubicin—ovarian cancer	0.00986	0.0199	CcSEcCtD
Cycloserine—Drug hypersensitivity—Doxorubicin—ovarian cancer	0.00912	0.0184	CcSEcCtD
Cycloserine—DDC—Tryptophan metabolism—CYP1B1—ovarian cancer	0.00601	0.0315	CbGpPWpGaD
Cycloserine—DDC—Parkinsons Disease Pathway—CCNE1—ovarian cancer	0.00577	0.0302	CbGpPWpGaD
Cycloserine—Cardiac failure congestive—Paclitaxel—ovarian cancer	0.00556	0.0112	CcSEcCtD
Cycloserine—Tremor—Chlorambucil—ovarian cancer	0.00555	0.0112	CcSEcCtD
Cycloserine—Convulsion—Chlorambucil—ovarian cancer	0.00513	0.0104	CcSEcCtD
Cycloserine—SLC36A2—Transmembrane transport of small molecules—AQP3—ovarian cancer	0.00511	0.0268	CbGpPWpGaD
Cycloserine—SLC36A2—SLC-mediated transmembrane transport—SLC5A5—ovarian cancer	0.00509	0.0266	CbGpPWpGaD
Cycloserine—SLC36A2—SLC-mediated transmembrane transport—SLC2A1—ovarian cancer	0.00491	0.0257	CbGpPWpGaD
Cycloserine—SLC36A2—Transmembrane transport of small molecules—ATP7B—ovarian cancer	0.0049	0.0257	CbGpPWpGaD
Cycloserine—Confusional state—Chlorambucil—ovarian cancer	0.00488	0.00985	CcSEcCtD
Cycloserine—Cardiac failure congestive—Docetaxel—ovarian cancer	0.00471	0.00951	CcSEcCtD
Cycloserine—Convulsion—Melphalan—ovarian cancer	0.00448	0.00904	CcSEcCtD
Cycloserine—DDC—Circadian rythm related genes—TOP1—ovarian cancer	0.00425	0.0222	CbGpPWpGaD
Cycloserine—Dysarthria—Epirubicin—ovarian cancer	0.0042	0.00848	CcSEcCtD
Cycloserine—Vertigo—Vinorelbine—ovarian cancer	0.00405	0.00819	CcSEcCtD
Cycloserine—Feeling abnormal—Chlorambucil—ovarian cancer	0.00399	0.00805	CcSEcCtD
Cycloserine—Dysarthria—Doxorubicin—ovarian cancer	0.00388	0.00784	CcSEcCtD
Cycloserine—SLC36A2—Transmembrane transport of small molecules—TUBB3—ovarian cancer	0.00387	0.0203	CbGpPWpGaD
Cycloserine—Paraesthesia—Topotecan—ovarian cancer	0.00387	0.00781	CcSEcCtD
Cycloserine—Paraesthesia—Melphalan—ovarian cancer	0.00379	0.00764	CcSEcCtD
Cycloserine—DDC—Circadian rythm related genes—PPP1CC—ovarian cancer	0.00371	0.0194	CbGpPWpGaD
Cycloserine—Coma—Epirubicin—ovarian cancer	0.00363	0.00732	CcSEcCtD
Cycloserine—Hypersensitivity—Chlorambucil—ovarian cancer	0.00356	0.0072	CcSEcCtD
Cycloserine—Feeling abnormal—Topotecan—ovarian cancer	0.00355	0.00716	CcSEcCtD
Cycloserine—Coma—Doxorubicin—ovarian cancer	0.00336	0.00678	CcSEcCtD
Cycloserine—Paraesthesia—Vinorelbine—ovarian cancer	0.00331	0.00668	CcSEcCtD
Cycloserine—DDC—Circadian rythm related genes—HNF1B—ovarian cancer	0.00322	0.0169	CbGpPWpGaD
Cycloserine—Cardiac failure congestive—Epirubicin—ovarian cancer	0.00318	0.00642	CcSEcCtD
Cycloserine—Hypersensitivity—Topotecan—ovarian cancer	0.00317	0.00641	CcSEcCtD
Cycloserine—Hypersensitivity—Melphalan—ovarian cancer	0.00311	0.00627	CcSEcCtD
Cycloserine—Feeling abnormal—Vinorelbine—ovarian cancer	0.00303	0.00613	CcSEcCtD
Cycloserine—DDC—Dopaminergic Neurogenesis—STAT3—ovarian cancer	0.00298	0.0156	CbGpPWpGaD
Cycloserine—Cardiac failure congestive—Doxorubicin—ovarian cancer	0.00294	0.00594	CcSEcCtD
Cycloserine—DDC—Parkinsons Disease Pathway—CASP3—ovarian cancer	0.00293	0.0153	CbGpPWpGaD
Cycloserine—Osteoarthritis—Epirubicin—ovarian cancer	0.00288	0.00582	CcSEcCtD
Cycloserine—Tremor—Paclitaxel—ovarian cancer	0.00284	0.00574	CcSEcCtD
Cycloserine—Vertigo—Paclitaxel—ovarian cancer	0.00273	0.00551	CcSEcCtD
Cycloserine—Rash—Topotecan—ovarian cancer	0.00271	0.00548	CcSEcCtD
Cycloserine—Hypersensitivity—Vinorelbine—ovarian cancer	0.00271	0.00548	CcSEcCtD
Cycloserine—Dermatitis—Topotecan—ovarian cancer	0.00271	0.00548	CcSEcCtD
Cycloserine—Headache—Topotecan—ovarian cancer	0.0027	0.00545	CcSEcCtD
Cycloserine—Osteoarthritis—Doxorubicin—ovarian cancer	0.00267	0.00538	CcSEcCtD
Cycloserine—Rash—Melphalan—ovarian cancer	0.00266	0.00537	CcSEcCtD
Cycloserine—Dermatitis—Melphalan—ovarian cancer	0.00266	0.00536	CcSEcCtD
Cycloserine—Convulsion—Paclitaxel—ovarian cancer	0.00263	0.00531	CcSEcCtD
Cycloserine—SLC36A2—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	0.00258	0.0135	CbGpPWpGaD
Cycloserine—Confusional state—Paclitaxel—ovarian cancer	0.0025	0.00504	CcSEcCtD
Cycloserine—SLC36A2—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	0.0025	0.0131	CbGpPWpGaD
Cycloserine—Rash—Vinorelbine—ovarian cancer	0.00232	0.00469	CcSEcCtD
Cycloserine—Dermatitis—Vinorelbine—ovarian cancer	0.00232	0.00469	CcSEcCtD
Cycloserine—Headache—Vinorelbine—ovarian cancer	0.00231	0.00466	CcSEcCtD
Cycloserine—Convulsion—Docetaxel—ovarian cancer	0.00223	0.0045	CcSEcCtD
Cycloserine—Paraesthesia—Paclitaxel—ovarian cancer	0.00222	0.00449	CcSEcCtD
Cycloserine—Drowsiness—Epirubicin—ovarian cancer	0.00222	0.00448	CcSEcCtD
Cycloserine—Somnolence—Paclitaxel—ovarian cancer	0.0022	0.00445	CcSEcCtD
Cycloserine—Confusional state—Docetaxel—ovarian cancer	0.00212	0.00428	CcSEcCtD
Cycloserine—DDC—Amino acid and derivative metabolism—SLC5A5—ovarian cancer	0.00211	0.011	CbGpPWpGaD
Cycloserine—Drowsiness—Doxorubicin—ovarian cancer	0.00205	0.00415	CcSEcCtD
Cycloserine—Feeling abnormal—Paclitaxel—ovarian cancer	0.00204	0.00412	CcSEcCtD
Cycloserine—SLC36A2—Transmembrane transport of small molecules—ABCB1—ovarian cancer	0.00197	0.0103	CbGpPWpGaD
Cycloserine—Paraesthesia—Docetaxel—ovarian cancer	0.00189	0.00381	CcSEcCtD
Cycloserine—Somnolence—Docetaxel—ovarian cancer	0.00187	0.00377	CcSEcCtD
Cycloserine—Hypersensitivity—Paclitaxel—ovarian cancer	0.00183	0.00369	CcSEcCtD
Cycloserine—Feeling abnormal—Docetaxel—ovarian cancer	0.00173	0.00349	CcSEcCtD
Cycloserine—Rash—Paclitaxel—ovarian cancer	0.00156	0.00315	CcSEcCtD
Cycloserine—Dermatitis—Paclitaxel—ovarian cancer	0.00156	0.00315	CcSEcCtD
Cycloserine—Vertigo—Epirubicin—ovarian cancer	0.00156	0.00315	CcSEcCtD
Cycloserine—Headache—Paclitaxel—ovarian cancer	0.00155	0.00313	CcSEcCtD
Cycloserine—Hypersensitivity—Docetaxel—ovarian cancer	0.00155	0.00312	CcSEcCtD
Cycloserine—Convulsion—Epirubicin—ovarian cancer	0.0015	0.00304	CcSEcCtD
Cycloserine—DDC—Circadian rythm related genes—TYMS—ovarian cancer	0.0015	0.00783	CbGpPWpGaD
Cycloserine—Vertigo—Doxorubicin—ovarian cancer	0.00144	0.00291	CcSEcCtD
Cycloserine—Confusional state—Epirubicin—ovarian cancer	0.00143	0.00288	CcSEcCtD
Cycloserine—Convulsion—Doxorubicin—ovarian cancer	0.00139	0.00281	CcSEcCtD
Cycloserine—Rash—Docetaxel—ovarian cancer	0.00132	0.00267	CcSEcCtD
Cycloserine—Dermatitis—Docetaxel—ovarian cancer	0.00132	0.00267	CcSEcCtD
Cycloserine—Confusional state—Doxorubicin—ovarian cancer	0.00132	0.00267	CcSEcCtD
Cycloserine—Headache—Docetaxel—ovarian cancer	0.00132	0.00266	CcSEcCtD
Cycloserine—DDC—Metabolism—NME2—ovarian cancer	0.00128	0.00668	CbGpPWpGaD
Cycloserine—Paraesthesia—Epirubicin—ovarian cancer	0.00127	0.00257	CcSEcCtD
Cycloserine—Somnolence—Epirubicin—ovarian cancer	0.00126	0.00254	CcSEcCtD
Cycloserine—Paraesthesia—Doxorubicin—ovarian cancer	0.00118	0.00238	CcSEcCtD
Cycloserine—Feeling abnormal—Epirubicin—ovarian cancer	0.00117	0.00236	CcSEcCtD
Cycloserine—Somnolence—Doxorubicin—ovarian cancer	0.00116	0.00235	CcSEcCtD
Cycloserine—Feeling abnormal—Doxorubicin—ovarian cancer	0.00108	0.00218	CcSEcCtD
Cycloserine—Hypersensitivity—Epirubicin—ovarian cancer	0.00104	0.00211	CcSEcCtD
Cycloserine—DDC—SIDS Susceptibility Pathways—CXCL8—ovarian cancer	0.00099	0.00518	CbGpPWpGaD
Cycloserine—Hypersensitivity—Doxorubicin—ovarian cancer	0.000965	0.00195	CcSEcCtD
Cycloserine—DDC—SIDS Susceptibility Pathways—CASP3—ovarian cancer	0.000947	0.00496	CbGpPWpGaD
Cycloserine—DDC—SIDS Susceptibility Pathways—CTNNB1—ovarian cancer	0.000913	0.00478	CbGpPWpGaD
Cycloserine—Rash—Epirubicin—ovarian cancer	0.000893	0.0018	CcSEcCtD
Cycloserine—Dermatitis—Epirubicin—ovarian cancer	0.000892	0.0018	CcSEcCtD
Cycloserine—Headache—Epirubicin—ovarian cancer	0.000887	0.00179	CcSEcCtD
Cycloserine—Rash—Doxorubicin—ovarian cancer	0.000826	0.00167	CcSEcCtD
Cycloserine—Dermatitis—Doxorubicin—ovarian cancer	0.000825	0.00167	CcSEcCtD
Cycloserine—DDC—Metabolism—CYTB—ovarian cancer	0.000823	0.00431	CbGpPWpGaD
Cycloserine—Headache—Doxorubicin—ovarian cancer	0.000821	0.00166	CcSEcCtD
Cycloserine—DDC—SIDS Susceptibility Pathways—VEGFA—ovarian cancer	0.000804	0.00421	CbGpPWpGaD
Cycloserine—DDC—Circadian rythm related genes—PTEN—ovarian cancer	0.000727	0.0038	CbGpPWpGaD
Cycloserine—DDC—Metabolism—BRIP1—ovarian cancer	0.000719	0.00377	CbGpPWpGaD
Cycloserine—DDC—Metabolism—PPP1CC—ovarian cancer	0.000719	0.00377	CbGpPWpGaD
Cycloserine—DDC—SIDS Susceptibility Pathways—IL6—ovarian cancer	0.000556	0.00291	CbGpPWpGaD
Cycloserine—DDC—Circadian rythm related genes—TP53—ovarian cancer	0.000496	0.0026	CbGpPWpGaD
Cycloserine—DDC—Metabolism—YAP1—ovarian cancer	0.000482	0.00253	CbGpPWpGaD
Cycloserine—DDC—Circadian rythm related genes—IL6—ovarian cancer	0.000454	0.00238	CbGpPWpGaD
Cycloserine—DDC—Metabolism—FASN—ovarian cancer	0.000393	0.00206	CbGpPWpGaD
Cycloserine—DDC—Metabolism—SLC5A5—ovarian cancer	0.000387	0.00202	CbGpPWpGaD
Cycloserine—DDC—Metabolism—SLC2A1—ovarian cancer	0.000374	0.00196	CbGpPWpGaD
Cycloserine—DDC—Metabolism—CYP1B1—ovarian cancer	0.000358	0.00187	CbGpPWpGaD
Cycloserine—DDC—Metabolism—PPP2R1A—ovarian cancer	0.000318	0.00166	CbGpPWpGaD
Cycloserine—DDC—Metabolism—ABCB1—ovarian cancer	0.000295	0.00154	CbGpPWpGaD
Cycloserine—DDC—Metabolism—TYMS—ovarian cancer	0.00029	0.00152	CbGpPWpGaD
Cycloserine—DDC—Metabolism—CAV1—ovarian cancer	0.000233	0.00122	CbGpPWpGaD
Cycloserine—DDC—Metabolism—PIK3CG—ovarian cancer	0.000213	0.00111	CbGpPWpGaD
Cycloserine—DDC—Metabolism—PIK3CD—ovarian cancer	0.000187	0.000978	CbGpPWpGaD
Cycloserine—DDC—Metabolism—PIK3CB—ovarian cancer	0.000163	0.000853	CbGpPWpGaD
Cycloserine—DDC—Metabolism—PTEN—ovarian cancer	0.000141	0.000737	CbGpPWpGaD
Cycloserine—DDC—Metabolism—PIK3CA—ovarian cancer	9.93e-05	0.00052	CbGpPWpGaD
Cycloserine—DDC—Metabolism—AKT1—ovarian cancer	8.11e-05	0.000425	CbGpPWpGaD
